RFCA
ELGX

R&F Capital Advisors’s Endologix Inc ELGX Stock Holding History

R&F Capital Advisors’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-19,517
Closed -$1.12M – 889
2016
Q4 		$1.12M Buy
+19,517
New +$1.79M 0.39% 62

Other funds holding ELGX

BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

R&F Capital Advisors's ELGX Position: Q1 2017 in Review

R&F Capital Advisors sold out of Endologix Inc (ELGX) in Q1 2017, closing a stake of 19,517 shares — an estimated $1.12M sold.

R&F Capital Advisors first reported a position in ELGX in Q4 2016 and held it in 1 quarter. The position peaked at $1.12M in Q4 2016. 129 funds tracked by Wall St. Rank hold ELGX as of Q1 2017.

  • R&F Capital Advisors reported no remaining Endologix Inc position as of Q1 2017 after selling out during the quarter.
  • R&F Capital Advisors sold 19,517 Endologix Inc shares in Q1 2017, an estimated $1.12M.
  • R&F Capital Advisors first reported a position in Endologix Inc in Q4 2016 and held it in 1 quarter.
  • R&F Capital Advisors's Endologix Inc position peaked at $1.12M in Q4 2016.
  • 129 funds tracked by Wall St. Rank held Endologix Inc as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.